1 completed. 1 Phase 3.
| Phase | Trials | Status |
|---|---|---|
| Phase 3 | 1 | Completed 1 |
Follow IC-MPGN: new trials by email Literature Review of IC-MPGN trials Research Report on IC-MPGN
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| Phase III Study Assessing the Efficacy and Safety of Pegcetacoplan in Patients With C3 Glomerulopathy or Immune-Complex Membranoproliferative Glomerulonephritis Pegcetacoplan, Placebo - C3G, IC-MPGN | Phase 3 | Completed | Apellis Pharmaceuticals, Inc. | 124 | 2021-11-12 | 2026-01-29 |
Glomerulonephritis, Membranoproliferative (1)
Female Urogenital Diseases (1) · Female Urogenital Diseases and Pregnancy Complications (1) · Glomerulonephritis (1) · Immune System Diseases (1) · Kidney Diseases (1) · Male Urogenital Diseases (1) · Nephritis (1) · Urogenital Diseases (1) · Urologic Diseases (1)
pegcetacoplan (1)
Apellis Pharmaceuticals, Inc. (1)
Argentina (1) · Australia (1) · Austria (1) · Belgium (1) · Brazil (1) · Canada (1) · Czechia (1) · France (1) · Germany (1) · Israel (1) · Italy (1) · Japan (1) · Netherlands (1) · Poland (1) · South Korea (1)